- Home
- APRE vs MRKR Comparison
APRE vs MRKR Comparison
Compare APRE & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- MRKR
- Stock Information
- Founded
- APRE 2006
- MRKR N/A
- Country
- APRE United States
- MRKR United States
- Employees
- APRE N/A
- MRKR N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- APRE Health Care
- MRKR Health Care
- Exchange
- APRE Nasdaq
- MRKR Nasdaq
- Market Cap
- APRE 13.5M
- MRKR 11.8M
- IPO Year
- APRE 2019
- MRKR N/A
- Fundamental
- Price
- APRE $1.50
- MRKR $1.17
- Analyst Decision
- APRE Strong Buy
- MRKR Strong Buy
- Analyst Count
- APRE 2
- MRKR 3
- Target Price
- APRE $15.50
- MRKR $13.17
- AVG Volume (30 Days)
- APRE 29.2K
- MRKR 53.8K
- Earning Date
- APRE 05-13-2025
- MRKR 05-14-2025
- Dividend Yield
- APRE N/A
- MRKR N/A
- EPS Growth
- APRE N/A
- MRKR N/A
- EPS
- APRE N/A
- MRKR N/A
- Revenue
- APRE $1,502,581.00
- MRKR $6,591,080.00
- Revenue This Year
- APRE N/A
- MRKR N/A
- Revenue Next Year
- APRE N/A
- MRKR N/A
- P/E Ratio
- APRE N/A
- MRKR N/A
- Revenue Growth
- APRE 157.63
- MRKR 99.06
- 52 Week Low
- APRE $1.41
- MRKR $0.95
- 52 Week High
- APRE $5.90
- MRKR $5.99
- Technical
- Relative Strength Index (RSI)
- APRE 27.07
- MRKR 47.32
- Support Level
- APRE $1.41
- MRKR $0.99
- Resistance Level
- APRE $1.59
- MRKR $1.25
- Average True Range (ATR)
- APRE 0.11
- MRKR 0.10
- MACD
- APRE 0.02
- MRKR 0.03
- Stochastic Oscillator
- APRE 18.60
- MRKR 73.33
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.